Journal profile · ONCOLOGY
Journal of Cancer Survivorship
ISSN 1932-2259 · eISSN 1932-2267 · Springer US · UNITED STATES · 6 issues per year · Founded 2007
Journal of Cancer Survivorship: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 3.3; hybrid open access; APC about USD 4,790; median 91 days to acceptance (107 articles, last 24 months); 219 articles in 2025; indexed in SCIE, SSCI and Scopus.
The journal's website announces a move to full open access: We are pleased to announce that Journal of Cancer Survivorship will become a fully open access (OA) on 1 January 2027. Source ↗Publisher website ·
Scope
Aims, scope and focus
Journal of Cancer Survivorship is published by Springer US and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cancer survivorship and care, Cancer-related cognitive impairment studies and Childhood Cancer Survivors' Quality of Life, together about 57.8% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Announcement We are pleased to announce that Journal of Cancer Survivorship will become a fully open access (OA) on 1 January 2027. As a result, all submissions received from 8 September 2026 are subject to an article publication charge (APC) if accepted and published in the journal (unless a waiver is applied). Please see our FAQs which can be found at the bottom of this page for more information on APCs, funding options, waivers and the journal's transition to fully open access. The Journal of Cancer Survivorship: Research and Practice publishes original research on cancer survivors, systematic, and meta-analytic literature reviews, clinical investigations and policy-related research that can impact the quality of care and quality of life of cancer survivors. The journal publishes peer reviewed papers related to improving the understanding, prevention, and management of multiple areas related to cancer survivorship that can affect quality care, symptom management, function, and well-being.The number of cancer survivors continue to increase worldwide. This journal considers cancer survivors as individuals who were diagnosed with and treated for cancer (either living with or free of cancer), as well as those who after primary treatment continue to receive prolonged treatment. Studies can include adolescents or adults treated for cancer as children, as well as young adults, adults, or older adults. Research and practice involving all these types of cancer survivors is growing rapidly and dissemination of evidence-based information is essential for improved understanding and care. Publishes basic research, epidemiological studies, clinical investigations, health services and policy-related research Publishes systematic, meta-analytic and scoping reviews that adhere to the PRISMA reporting guidelines for systematic reviews/meta-analyses or the PRISMA extension for scoping reviews Improves understanding of survivorship topics affecting quality of care, health, function, and well-being Reflects growing interest consistent with increasing prevalence rates and future global impact For authors: Checklists to improve communication of quantitative or qualitative scientific researchMany papers that are published in JCS tend to follow various STROBE checklists https://www.strobe-statement.org/checklists/ or https://www.unisa.edu.au/contentassets/72bf75606a2b4abcaf7f17404af374ad/7c-10.1007_bf028206851.pdf or https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC1120242/ fo
From the journal's Aims & Scope
Research area (LetPub): ONCOLOGY
Editor-in-chief Michael FeuersteinPublisher website
Editorial board by country: none in mainland China; most named United States 36, Canada 3, Australia 3, Netherlands 3, Hong Kong, China 1 (52 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer survivorship and careMedicine34.4%
- Cancer-related cognitive impairment studiesMedicine11.8%
- Childhood Cancer Survivors' Quality of LifeMedicine11.6%
- Economic and Financial Impacts of CancerEconomics, Econometrics and Finance4.4%
- Family Support in IllnessSocial Sciences4.3%
- Cancer Risks and FactorsMedicine3.5%
- Global Cancer Incidence and ScreeningMedicine3.4%
- Physical Activity and HealthMedicine2.3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 3 |
| Minor | Social Issues | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 3 |
| Minor | Social Issues | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Social Issues | Zone 2 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIESSCIScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEPsycINFOCurrent ContentsPublisher website
Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS, Semantic Scholar
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.3LetPub ·
- Impact factor (publisher) 2025
- 3.4Publisher website ·
- 5-year impact factor (publisher) 2025
- 4.3Publisher website ·
- CiteScore 2026-06
- 8.6LetPub ·
- SJR 2026-06
- 1.15LetPub ·
- SNIP 2026-06
- 1.43LetPub ·
- h-index
- 53LetPub ·
- h-index
- 109OpenAlex ·
- i10-index
- 1,201OpenAlex ·
- 2-year mean citedness
- 3.14OpenAlex ·
- Self-citation rate
- 8.8%LetPub ·
- Share of gold OA articles
- 47.42%LetPub ·
Volume
- Articles per year
- 212LetPub ·
- Articles per year (publisher)
- 2,025Publisher website ·
- Downloads per year (publisher) 2025
- 1,100,000Publisher website ·
Articles by year OpenAlex count · 2,098 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 168 | 106 | 62 |
| 2025 | 219 | 143 | 508 |
| 2024 | 222 | 156 | 1,342 |
| 2023 | 195 | 136 | 2,222 |
| 2022 | 181 | 125 | 2,966 |
| 2021 | 163 | 105 | 3,683 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
91 daysMedian, submission to acceptance · P25–P75 73 days – 133 days
- Acceptance to online
- median 17 days (107 articles)
- Submission to online
- median 112 days
- Sample
- 107 articles with submission and acceptance dates (443 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- over 12 weeksLetPub ·
- Submission to first decision
- 1 daysPublisher website ·
- Peer review
- Single anonymous peer review, Double anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,790 / EUR 3,690 / GBP 2,990 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare3 items from the author guidelines
- Abstract
- 150–250 words
- Keywords
- ≥ 4
- Reference style
- Numbered, in order of citation
Article types accepted1
- editorialSingle-blind peer review This journal follows a single-blind reviewing procedure. Authors are therefore requested to submit a title page, containing title, all …Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, Publication ethics, License & copyright, Open access, Peer review, Trial registration / reporting guidelines
- AI use Generative AI Images
Please check Springer’s policy on generative AI images and make sure your work adheres to the principles described therein. Back to top
Source ↗Publisher website ·- Authorship Authorship principles
Structured abstract of 150 to 250 words with sections Purpose, Methods, Results, Conclusions, Implications for Cancer Survivors Model summary
These guidelines describe authorship principles and good authorship practices to which prospective authors should adhere to. Authorship clarified The Journal and Publisher assume all authors agreed with the content and that all gave explicit consent to submit and that they obtained consent from the responsible authorities at the institute/organization where the work has been carried out, before th…
Source ↗Publisher website ·- Conflicts of interest Disclosures and declarations
All authors are requested to include information regarding sources of funding, financial or non-financial interests, study-specific approval by the appropriate ethics committee for research involving humans and/or animals, informed consent if the research involved human participants, and a statement on welfare of animals if the research involved animals (as appropriate). The decision whether such …
Source ↗Publisher website ·- Data availability Data Availability
Optional data availability statement Model summary
This journal encourages authors to provide an optional statement of data availability in their article. Data Availability Statements should include information on where data supporting the results reported in the article can be found, including, where applicable, hyperlinks to publicly archived datasets analysed or generated during the study. Data availability statements can also indicate whether …
Source ↗Publisher website ·- Publication ethics Compliance with Ethical Standards
Ethics approval statement required for research involving human or animal subjects Model summary
To ensure objectivity and transparency in research and to ensure that accepted principles of ethical and professional conduct have been followed, authors should include information regarding sources of funding, potential conflicts of interest (financial or non-financial), informed consent if the research involved human participants, and a statement on welfare of animals if the research involved an…
Source ↗Publisher website ·- License & copyright Copyright
Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under a Creative Commons license. Details of the OA licences offered to authors can be found on the individual journal website, in the journal's How to publish with us guide. Back to top
Source ↗Publisher website ·- Open access Open access publishing
To find out more about publishing your work Open Access in Journal of Cancer Survivorship, including information on fees, funding and licences, visit our Open access publishing page. Back to top
Source ↗Publisher website ·- Peer review Single-blind peer review
Single-blind peer review Model summary
This journal follows a single-blind reviewing procedure. Authors are therefore requested to submit a title page, containing title, all author names, affiliations, and the contact information of the corresponding author. Any acknowledgements, disclosures, or funding information should also be included on this page. Back to top
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical Trial Registration
The World Health Organization (WHO) definition of a clinical trial is "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes". The WHO defines health interventions as “A health intervention is an act performed for, with or on behalf of a person or population whose purpose is to ass…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer US
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- 6 issues per year
- Founded
- 2007
- ISSN
- 1932-2259
- Electronic ISSN
- 1932-2267
- Latest issue on the website
- Volume 20, Issue 4 (August 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Journal of Cancer Survivorship
What CAS zone is Journal of Cancer Survivorship in?
In the 2025 upgraded edition of the CAS Journal Ranking, Journal of Cancer Survivorship is in Zone 2 of Medicine, and in Zone 3 of the minor category Oncology / Social Issues. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Journal of Cancer Survivorship?
The latest impact factor listed by LetPub is 3.3; CiteScore 8.6, h-index 109.
How long does peer review take at Journal of Cancer Survivorship?
Based on the dates recorded on 107 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 91 days (interquartile range 73–133 days); authors report an average review time of over 12 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Journal of Cancer Survivorship?
According to the journal's author guidelines: Abstract: 150–250 words; Keywords: ≥ 4; Reference style: Numbered, in order of citation. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Journal of Cancer Survivorship based?
Of the 52 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (36), Canada (3) and Australia (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Journal of Cancer Survivorship?
According to LetPub and DOAJ records, Journal of Cancer Survivorship is indexed in SCIE, SSCI and Scopus. The journal's website also lists MEDLINE, PsycINFO and Current Contents; that list has not been checked against each database.
Is Journal of Cancer Survivorship open access, and what is the APC?
Journal of Cancer Survivorship is a hybrid journal. For open-access publication: APC about USD 4,790.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .